Verona Pharma 2024 respiratory disease therapy investor presentation

Verona Pharma presents its pipeline for developing innovative respiratory disease therapies, focusing on Ohtuvayre for COPD treatment. The company maintains a strong financial position with $404.6M in cash and equivalents as of June 2024, supported by debt facilities providing future draws up to $425M. The presentation outlines commercialization strategies and market positioning for its lead therapeutic candidate.